Dr. Ronald Goldenberg is a consultant endocrinologist affiliated with North York General Hospital in Toronto, Ontario and LMC Diabetes & Endocrinology in Thornhill. His major areas of interest include clinical care of diabetes, obesity, dyslipidemia and thyroid disorders. Dr. Goldenberg is a past Medical Director of the Diabetes Education Centre at NYGH and North York Branson Hospital. He is a past chair of the Ontario Medical Association Section on Endocrinology & Metabolism and a previous President of the Toronto Diabetes Association.
Dr. Goldenberg is a councillor on the 2010-2014 Diabetes Canada Clinical & Scientific Section Executive Committee and a member of the Steering Committee for the 2013 Diabetes Canada Clinical Practice Guidelines, the Executive Board of the Canadian Society for the Study of the Aging Male, Diabetes Canada, American Diabetes Association, Endocrine Society, American Association of Endocrinologists, European Association for the Study of Diabetes, Canadian Society of Endocrinology & Metabolism and a Fellow of The American College of Endocrinology.
Dr. Goldenberg has been an investigator in a wide array of clinical trials in the areas of diabetes, hypertension, obesity, and dyslipidemia. He has been actively involved in Continuing Medical Education for the last two decades and is a key opinion leader amongst community-based endocrinologists in the Toronto area. He has been awarded an Honorable Citation by the Medical Staff Association of North York General Hospital for excellence in the practice of endocrinology and dedication to patient care in the community.
Dr. Goldenberg completed his residency in Internal Medicine in 1987 at the University of Toronto, and his fellowship in Endocrinology & Metabolism in 1989 at the University of Toronto.
Industry Expertise (4)
Health and Wellness
Health Care - Services
Areas of Expertise (7)
University of Toronto: MD., Internal Medicine 1987
University of Toronto: Residency Program, Internal Medicine 1987
- HealthChoiceFirst : Endocrinologist
Media Appearances (2)
Novo Nordisk Marks 90 Years of Innovating Diabetes Care
Hosted by Vince Lamanna, speakers will include Dr. Ronald Goldenberg, Clinical Endocrinologist, North York General Hospital; Lars Rebien Sørensen, President & CEO, Novo Nordisk A/S; Rick Blickstead, President & CEO, CDA and Dr. Janet Hux, Chief Science Officer, CDA...
First-in-class type 2 diabetes medication approved in Canada
Canada News Wire online
"In clinical trials, INVOKANA™ had a great impact on patients by improving glycemic control, while reducing body weight and systolic blood pressure," said Dr. Ronald Goldenberg, endocrinologist, LMC Diabetes & Endocrinology. "INVOKANA™ was also associated with a low incidence of hypoglycemia, which is something that is often associated with diabetes medications. This new treatment provides an exciting option for physicians and patients."...
The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, ...
The chronic hyperglycemia of diabetes is associated with significant longterm microvascular and macrovascular complications. A fasting plasma glucose level of 7.0 mmol/L, a 2-hour plasma glucose value in a 75 g oral glucose tolerance test of 11.1 mmol/L or a glycated ...
As people with type 2 diabetes form a heterogeneous group, treatment regimens and therapeutic targets should be individualized. As type 2 diabetes is characterized by insulin resistance and ongoing decline in beta cell function, glucose levels likely will worsen over ...
In the absence of evidence for interventions to prevent or delay type 1 diabetes, screening for type 1 diabetes is not recommended. Screening for type 2 diabetes using a fasting plasma glucose (FPG) and/or glycated hemoglobin (A1C) should be performed every 3 ...
Background: Insulin and incretin agents (dipeptidyl peptidase-4 inhibitors [DPP4is] and glucagon-like peptide-1 receptor agonists [GLP1 RAs]) are second-line treatment options in patients with type 2 diabetes (T2D) not achieving glycemic targets with ...